ArticleNature cancer2021

Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.

Won Jin Ho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.